Who We Are

The COVID-19 Prevention Network (CoVPN) was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health to respond to the global pandemic. Using the infectious disease expertise of their existing research networks and global partners, NIAID has directed the networks to utilize their experience and expertise to address the pressing need for vaccines and antibodies against the SARS-CoV-2 virus.

COVID-19 Prevention Network (CoVPN)

The UCSD Mother-Child-Adolescent Programprovides comprehensive, family centered care of women, children, youth and families. This internationally recognized multidisciplinaryspecialists provides medical care, clinical research trials, patient education, counseling, case management, peer advocacy, and community education. Its team of investigators is highly experienced in vaccine clinical trials with an emphasis on the prevention of respiratory viral diseases.

To Conduct Phase 3 Efficacy Trials to prevent infection and COVID-19 disease. CoVPN will work to develop and conduct studies to ensure rapid and thorough evaluation of United States government-sponsored COVID-19 vaccines and antibodies for the prevention of COVID-19 disease.

The CoVPN expects to open four Phase III vaccine efficacy trials trials that make sure the vaccine works - in 2020, with the potential for additional trials to follow. Each study is anticipated to enroll roughly 30,000 people, and participants will either get the vaccine product or a sterile saltwater injection (placebo). Some trials may be conducted only in the United States, while others will enroll global communities.

The first Phase III vaccine trial will be of the Moderna mRNA vaccine that is planned to begin enrollment in the end of July 2020.

These efficacy trials hope to enroll persons who are at risk for exposure to SARS-CoV-2. This risk could be associated with, but is not limited to:

Read the original:

Overview of the COVID-19 Prevention Network Study - UC San Diego Health